新药周观点：ESMO2024、WCLC2024闭幕，国产ADC、双抗披露多个优异数据

Investment Rating - The report maintains an "Outperform" rating for the biotechnology sector, indicating a positive outlook compared to the market [5]. Core Insights - The report highlights significant advancements in the ADC (Antibody-Drug Conjugates) and bispecific antibody sectors, with domestic companies leading in innovation and clinical data, suggesting potential for continued overseas licensing opportunities [2][21]. - Key data from recent conferences (ASCO 2024, WCLC 2024) showcased promising results for various therapies, particularly in the treatment of NSCLC (Non-Small Cell Lung Cancer) and other cancers [2][21]. - The report notes that 87 new drug INDs (Investigational New Drug applications) were approved domestically, with 18 INDs accepted and 5 NDAs (New Drug Applications) received [3][21]. Summary by Sections New Drug Market Review - From September 16 to September 20, 2024, the top five companies in the new drug sector by stock performance were: - Haichuang Pharmaceutical (19.67%) - Yasheng Pharmaceutical (15.99%) - Gilead Sciences (14.94%) - Oconvision (10.28%) - Heptares Therapeutics (9.73%) - The companies with the largest declines were: - Chuangsheng Group (-13.33%) - Shouyao Holdings (-11.78%) - Rongchang Biotech (-10.00%) - Deqi Pharmaceuticals (-8.33%) - Betta Pharmaceuticals (-7.76%) [1][16]. Key Analysis of New Drug Sector - The report emphasizes the innovative progress in ADC and bispecific antibody fields, with several companies presenting excellent clinical data at major conferences. Notable mentions include: - Kangfang Biotech's PD-1/VEGF bispecific antibody AK112 showing superior data in first-line treatment for PD-L1 positive NSCLC. - Innovent Biologics' PD-1/IL-2α-bias bispecific antibody demonstrating strong results in NSCLC and colorectal cancer [2][21]. - ADC developments include: - Kelun Biotech's TROP2 ADC SKB264 showing promising data in cervical cancer. - Bai Li Tianheng's EGFR/HER3 bispecific ADC BL-B01D1 with positive results in esophageal and urinary tract cancers [2][21]. New Drug Approvals and Applications - The report details the approval and acceptance of new drugs, including: - Heng Rui Medicine's new drug application for Rilaforpu-α injection for advanced gastric cancer received acceptance from China's NMPA [3][21]. - Lepu Biotech's EGFR ADC for recurrent/metastatic nasopharyngeal carcinoma proposed for priority review [3][21]. Overseas New Drug Highlights - Key developments in the overseas market include: - Bristol-Myers Squibb and Regeneron presenting data on their LAG-3 targeted therapy combined with PD-1 inhibitors for advanced cancer treatment. - Daiichi Sankyo and Merck announcing their antibody-drug conjugate achieving primary endpoints in clinical trials [7].